MedTrace Logo

Assessment of Early-detection Based on Liquid Biopsy in Lymphoid Malignancies

NCT05275036 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 493

Last updated 2022-04-14

No results posted yet for this study

Summary

ASCEND-LYM is a prospective, multi-center, observational study aimed at detecting early stage lymphoma and constrcuting prognostic model by combined assays of cfDNA methylation and other biomarkers. The study will enroll approximately 493 participants including lymphoid malignancies and benign diseases.

Conditions

Interventions

DEVICE

early detection test

Blood collection and early detection testing

Sponsors & Collaborators

  • Guangzhou Burning Rock Dx Co., Ltd.

    collaborator INDUSTRY

  • Sun Yat-sen University

    lead OTHER

Principal Investigators

  • Huiqiang Huang, Ph.D · Department of Medical Oncology, Sun Yat-sen University Cancer Center

Eligibility

Min Age
40 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-05-31
Primary Completion
2023-06-30
Completion
2025-08-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05275036 on ClinicalTrials.gov